Ruthenium(II)/4,6-dimethyl-2-mercaptopyrimidine complexes: synthesis, characterization, X-ray structures and in vitro cytotoxicity activities on cancer cell lines by Mondelli, Melina A. et al.
  Universidade de São Paulo
 
2014-01
 
Ruthenium(II)/4,6-dimethyl-2-
mercaptopyrimidine complexes: synthesis,
characterization, X-ray structures and in vitro
cytotoxicity activities on cancer cell lines
 
 
Polyhedron,Amsterdam : Elsevier,v. 68, p. 312-318, Jan. 2014
http://www.producao.usp.br/handle/BDPI/50514
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Física e Ciência Interdisciplinar - IFSC/FCI Artigos e Materiais de Revistas Científicas - IFSC/FCI
Ruthenium(II)/4,6-dimethyl-2-mercaptopyrimidine complexes:
Synthesis, characterization, X-ray structures and in vitro cytotoxicity
activities on cancer cell lines
Melina A. Mondelli a, Angelica E. Graminha a, Rodrigo S. Corrêa a, Monize M. da Silva a, Andréa P. Carnizello a,
Gustavo Von Poelhsitz b,⇑, Javier Ellena c, Victor M. Deﬂon d, Giovanni F. Caramori e, Maria H. Torre f,
Denise C. Tavares g, Alzir A. Batista a,⇑
aDepartamento de Química, Universidade Federal de São Carlos, CP 676, CEP 13565-905 São Carlos, SP, Brazil
b Instituto de Química, Universidade Federal de Uberlândia, CP 593, CEP 38400-902 Uberlândia, MG, Brazil
c Instituto de Física de São Carlos, Universidade de São Paulo, CP 369, CEP 13560-970 São Carlos, SP, Brazil
d Instituto de Química de São Carlos, Universidade de São Paulo, CP 369, CEP 13566-590 São Carlos, SP, Brazil
eDepartamento de Química – CFM, Universidade Federal de Santa Catarina – UFSC, Campus Universitário Trindade, CP 476, CEP 88040-900 Florianópolis, SC, Brazil
fCátedra de Química Inorgánica, Departamento Estrella Campos, Facultad de Química, Universidad de La República, Montevideo, Uruguay
gUniversidade de Franca, CEP 14404-600 Franca, SP, Brazil
a r t i c l e i n f o
Article history:
Received 11 July 2013
Accepted 4 November 2013
Available online 8 November 2013
Keywords:
Ruthenium(II)
Nitrosyl
Cytotoxicity
Crystal structure
dppb
4,6-Dimethyl-2-mercaptopyrimidine
a b s t r a c t
The complexes [RuCl(SpymMe2-N,S)2(NO)] (1) and [Ru(dppb)(SpymMe2-N,S)2] (2) (dppb = 1,4-
bis(diphenylphosphino)butane, SpymMe2 = deprotonated 4,6-dimethyl-2-mercaptopyrimidine) were
obtained and characterized by elemental analysis, spectroscopic techniques including X-ray crystallogra-
phy, conductimetry and cyclic voltammetry. Energy Decomposition Analysis (EDA) calculation indicated
strong intermolecular interaction between monomers of complex 1, as suggested by the 1H NMR spec-
trum of this complex, in chloroform solution. Additionally, preliminary tests were carried out, in order
to evaluate the cytotoxicity activity on cancer cell lines of the new complexes, and the free ligands,
against MDA-MB-231 (breast cancer), Hela (cervical cancer), U251 (glioma cancer) tumor cell lines and
the V79 (Chinese lung ﬁbroblast hamster) cell line. The best result was obtained for the complex 1 with
IC50 value of 0.11 ± 0.02, against MDA-MB-231 tumor cells.
 2013 Elsevier Ltd. All rights reserved.
1. Introduction
It is well established that metal-based chemotherapy is an
option for cancer treatment [1–7]. The success of cisplatin, carbo-
platin and oxaliplatin as anticancer agents has stimulated the
search for cytotoxic of transition metal compounds with more
acceptable toxicity proﬁle and expansion of activity [2,7,8]. In this
sense other classes of metal compounds, the potential non
platinum metallodrugs, have been developed and extensively
investigated in the search of new anticancer drugs [9,10]. Some
of these compounds have showed a promising activity, with bio-
logical features, which are very different from those of classical
platinum compounds [11–13].
Speciﬁcally, ruthenium compounds are an interesting alterna-
tive to platinum and among them, the NAMI-A – [ImH][trans-
RuCl4(DMSO)(Im)] and the KP1019 – [ImH][trans-RuCl4(Im)2]
(Im = imidazole), have favorable in vitro and in vivo pharmacologi-
cal properties and successfully completed phase I clinical trials
[7,14]. Currently, NAMI-A, despite being poorly cytotoxic, is under-
going phase II clinical trials due its excellent antimetastatic prop-
erties. Previous works from this group reported the reactivity of
the SpymMe2 ligand with the complexes fac-[RuCl3(NO)(P-P)]
[P-P = 1,2-bis(diphenylphosphino)ethane and 1,2-bis(diphenyl-
phosphino)ethylene] and cis-[RuCl2(dppb)(N-N)] (N-N = 2,20-
bipyridine and 4,40-dimethyl-2,20-bipyridine), some of them
showing interesting in vitro cytotoxicity against human cancer cell
lines [15,16].
In this work, following our research on ruthenium-based drugs,
the synthesis, spectroscopic and electrochemical characterization
of two new complexes with formula [RuCl(SpymMe2-N,S)2(NO)]
(1) and [Ru(SpymMe2-N,S)2(dppb)] (2) are reported, including the
X-ray structures of both complexes. Besides, the preliminary
in vitro tests of cytotoxicity activities against different tumour cell
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lines and V79 (Chinese lung ﬁbroblast hamster) are also presented
and discussed.
2. Experimental
2.1. Materials for synthesis
Solvents were puriﬁed by standard methods. All chemicals used
were of reagent grade or comparable purity. The RuCl33H2O was
purchased from Aldrich. The ligands 1,4-bis(diphenylphos-
phino)butane (dppb) and 4,6-dimethyl-2-mercaptopyrimidine
(HSpymMe2) were used as received from Aldrich. The RuCl3-
NO2H2O, and the [RuCl2(dppb)(PPh3)] precursor complexes were
prepared according to published procedures [17,18].
2.2. Instrumentation
The infrared spectra were recorded using CsI pellets in an FTIR
Bomem-Michelson 102 spectrometer, in the 4000–200 cm1 re-
gion. UV–Vis spectra were recorded in a HP8452A (diode array)
spectrophotometer. All NMR experiments were performed at
293 K on a Bruker spectrometer, 9.4 Tesla, observing 1H at
400.13 and 31P{1H} at 161.98 MHz. The NMR spectra were recorded
in CDCl3, with TMS (1H) and 85% H3PO4 (31P{1H}) as internal and
external references, respectively. The splitting of proton and phos-
phorus resonances, respectively in the reported 1H and 31P{1H}
NMR spectra are deﬁned as s = singlet, d = doublet, t = triplet, and
m = multiplet. Cyclic and differential pulse voltammetry experi-
ments were carried out at room temperature in CH2Cl2 as solvent
containing 0.10 M Bu4NClO4 (TBAP) (FlukaPurum), with a BAS-
100B/W Bioanalytical Systems Inc. electrochemical analyzer, with-
out iR compensation, the working and auxiliary electrodes were
stationary Pt foils; a Luggin capillary probe was used and the refer-
ence electrode was Ag/AgCl. Under these conditions the ferrocene
is oxidized at 0.43 V (Fc+/Fc). For the differential pulse experiments
the speciﬁc parameters were: scan rate, 20 mV/s; pulse amplitude,
50 mV; sample width, 17 ms; pulse period, 200 ms; quiet time, 2 s.
The microanalyses were performed in the Microanalytical Labora-
tory of Universidade Federal de São Carlos, São Carlos (SP), with an
EA 1108 CHNS microanalyser (Fisions Instruments). Conductivities
were measured using 103 M solutions of CH2Cl2 of the complexes
at 25 C under N2, using a Micronal conductivity bridge, and are
quoted in units of lS cm1.
2.3. X-ray crystallography
Crystals of complexes 1 and 2 were grown by slow evaporation
of dichloromethane solutions at room temperature. The crystals
were mounted on an Enraf–Nonius Kappa-CCD diffractometer with
graphite-monochromated Mo Ka (k = 0.71073 Å) radiation. The ﬁ-
nal unit-cell parameters were based on all reﬂections. Data collec-
tions were made using the COLLECT program [19]; integration and
scaling of the reﬂections were performed with the HKL DENZO-
SCALEPACK system of programs [20]. Absorption correction was
carried out by the GAUSSIAN [21] method for 1 and ‘‘semiempirical’’
[22] for 2. The structures were solved by direct methods with
SHELXS-97 [23]. The model was reﬁned by full-matrix least squares
on F2 by means of SHELXL-97 [23]. All hydrogen atoms were stereo-
chemically positioned and reﬁned with a riding model. The ORTEP
views shown in Figs. 1 and 2 were prepared using ORTEP-3 for
Windows [24]. Hydrogen atoms on the aromatic rings were reﬁned
isotropically, each with a thermal parameter 20% greater than the
equivalent isotropic displacement parameter of the atom to which
it is bonded. The data collections and experimental details are
summarized in Table 1.
2.4. Computational methods
All calculations were performed with the quantum chemistry
package GAMESS [25], in which the EDA analysis was implemented
by Su and Li [26]. The EDA analysis was performed at DFT level,
employing the model M06/def2-SV(P) [27,28]. The counterpoise
(CP) methods proposed by Boys and Bernardi for correcting basis
set superposition error, BSSE, was not employed in this case, since
DFT-SCF interactions are divergent when supermolecule basis set
is used [29]. Chemcraft1.6 package was employed to prepare input
ﬁles and to visualize structures (Figs. 2 and 3).
2.5. Synthesis
2.5.1. [RuCl(SpymMe2-N,S)2(NO)] (1)
To a solution of RuCl3(NO)2H2O (70.0 mg; 0.26 mmol) in 5 mL
of methanol, HSpymMe2 (7.57 mg; 0.54 mmol) dissolved in
5.0 mL of methanol, in the presence of 0.10 mL of triethylamine,
was added via cannula, and the contents of the ﬂask was stirred
for 24 h. The ﬁnal solution was concentrated to ca. 3 mL and excess
of water was added in order to obtain a precipitate. The solid was
ﬁltered off, well rinsed with water (3  5 mL) and diethyl ether
(3  5 mL) and dried in vacuo. Yield: 48 mg (39%). Anal. Calc. for
C12H14ClN5OS2RuH2O0.5CH3OH: exptl (calc) C, 29.05 (29.00); H,
3.17 (3.41); N, 13.22 (13.34); S, 14.41 (13.90). 1H NMR
(400.21 MHz, CDCl3, 298 K): d (ppm) 7.20 (s, 1H of SpymMe2);
6.70 (s, 1H of SpymMe2); 2.50 (s, 3H, CH3 of SpymMe2); 2.30 (s,
3H, CH3 of SpymMe2). UV–Vis (CH2Cl2, 105 M): k/nm (e/M1 -
cm1) 306 (1.16  104), 350 sh (4.19  103)396 sh (2.09  103). K
(CH2Cl2) 1.8 lS cm1.
2.5.2. [Ru(dppb)(SpymMe2-N,S)2] (2)
To a suspension of [RuCl2(dppb)(PPh3)] (70.0 mg; 0.08 mmol) in
10 mL of deaerated methanol, HSpymMe2 (25.2 mg; 0.18 mmol)
dissolved in 5.0 mL of methanol, in the presence of 0.10 mL of tri-
ethylamine, was added via cannula and the contents of the ﬂask
was stirred for 24 h. At the end of the reaction an orange precipi-
tate was formed, the yellow solution was concentrated to ca.
2 mL, in order to increase the amount of the precipitate. The solid
was ﬁltered off, well rinsed with water (3  5 mL) and diethyl
ether (3  5 mL) and dried in vacuo. Yield: 35 mg (53%). Anal. Calc.
for C40H42N4O4P2S2Ru: exptl (calc) C, 59.64 (59.61); H, 4.98 (5.25);
N, 6.98 (6.95); S, 8.01 (7.96). 1H NMR (400.21 MHz, CDCl3, 298 K): d
(ppm) 7.25 (s, 1H of SpymMe2); 6.68 (s, 1H of SpymMe2); 2.50 (s,
3H, CH3 of SpymMe2); 2.30 (s, 3H, CH3 of SpymMe2); 31P{1H}
NMR: d (ppm) 47.5 (s). UV–Vis (CH2Cl2, 105 M): k/nm (e/L mol1 -
cm1) 245 (2.41  104), 310 (8.51  104), 354 sh (6.19  103). K
(CH2Cl2) 3.3 lS cm1.
2.6. Cell culture assay (MDA-MB-231, Hela, U251 and V79)
In vitro cytotoxicity assays on cultured human tumor cell lines
still represent the standard method for the initial screening of anti-
tumoral agents. Thus, as a ﬁrst step in assessing their pharmaco-
logical properties, the new ruthenium complexes were assayed
against a human breast tumour cell lines MDA-MB-231, Hela,
U251(glioblastoma) and V79 (Chinese hamster ﬁbroblasts). The
cells were routinely maintained in Dulbecco’s Modiﬁed Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum
(FBS), at 37 C in a humidiﬁed 5% CO2 atmosphere. After reaching
conﬂuence, the cells were detached by trypsinization and counted.
For the cytotoxicity assay, 5  104 cells well1 were seeded in
200 lL of complete medium in 96-well assay microplates (Corning
Costar). The plates were incubated at 37 C in 5% CO2 for 24 h to al-
low cell adhesion, prior to drug testing. All tested compounds were
dissolved in sterile DMSO (stock solution with maximum
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concentration of 20 mM) and diluted to 5, 2, 1, 0.5, 0.2, 0.02 and
0.002 mM. From each of these dilute samples 2 lL aliquots were
added to 200 lL medium (without FBS) giving a ﬁnal concentration
of DMSO of approximately 1% and a ﬁnal concentration of the
complex diluted about 100 times. Cells were exposed to the com-
pounds for a 24 h-period. Cell respiration, as an indicator of cell
viability, was determined by the mitochondrial-dependent
reduction of MTT [30] (3-(4,5-dimethylthiazol-2-yl)-2,
Fig. 1. ORTEP view of complex 1 (a) and 2 (b) showing the atoms labeling and the 50% probability ellipsoids.
Fig. 2. Arrangement of two interacting monomers of complex 1, extracted from crystallographic data and employed to perform EDA.
Table 1
Crystallographic data and reﬁnement details for complexes 1 and 2.
Empirical formula 1 2
Formula weight 444.92 805.91
Temperature (K) 293(2) 293(2)
Crystal system orthorhombic triclinic
Space group P212121 P1
Unit cell dimensions
a (Å) 10.5309(3) 11.7322(2)
b (Å) 10.6960(2) 12.3193(2)
c (Å) 15.0784(5) 14.5400(3)
a () 95.8280(10)
b () 102.2490(10)
c () 110.9740(10)
V (Å3) 3924.19(8) 1880.97(6)
Z 4 2
Dcalc (g cm3) 1.740 1.423
Absorption coefﬁcient (mm1) 1.333 0.647
F(000) 888 832
h () 3.81–26.37 1.46–26.37
Limiting indices 13 6 h 6 13, 13 6 k 6 13, 17 6 l 6 18 14 6 h 6 4, 15 6 k 6 15, 18 6 l 6 18
Reﬂections collected 11295 28472
Independent reﬂections (Rint) 3415 (0.0319) 7649 (0.0177)
Data/restraints/parameters 3415/0/204 7649/0/446
Goodness-of-ﬁt (GOF) on F2 1.059 1.040
Final R indices [I > 2r(I)] R1 = 0.0307, wR2 = 0.0778 R1 = 0.0276, wR2 = 0.0707
R indices (all data) R1 = 0.0309, wR2 = 0.0781 R1 = 0.0313, wR2 = 0.0739
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5-diphenyltetrazolium bromide) or XTT (2,3-bis-(2-methoxy-4-ni-
tro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide)to formazan.
MTT or XTT solution (0.5 mg/mL) was added to cell cultures and
incubated for 3 h, after which 100 mL of isopropanol was added
to dissolve the precipitated formazan crystals. The conversion of
MTT to formazan by metabolically viable cells was monitored in
an automated microplate reader at 570 nm. The percent cell viabil-
ity was calculated by dividing the average absorbance of the cells
treated with the test compounds by that of the control; % cell via-
bility was plotted against drug concentration (logarithmic scale) to
determine the IC50 (drug concentration at which 50% of the cells
are viable relativeto the control), with the error estimated from
the average of 3 trials. For the use of XTT solution the experimental
procedure was followed as described in the literature [31].
3. Results and discussion
3.1. Synthesis of complexes
The nitrosyl derivative 1 was prepared from the classical pre-
cursor RuCl3NO.2H2O in analogy to previously reported procedures
for related nitrosyl ruthenium species [32]. Complex 2 was ob-
tained by treating the pseudo-pentacoordinated precursor [RuCl2
(dppb)(PPh3)] [18], with excess of the HSpymMe2 ligand. This
product is easily formed due to the great tendency of the precursor
to lose the PPh3 ligand. In these new complexes the deprotonate
form’SpymMe2’ act as chelate ligand, bonding the ruthenium ion
through both, the S and N-atoms (SpymMe2) as Scheme 1 shows.
This behavior was conﬁrmed by the X-ray structures.
3.2. Structural studies
The X-ray structures of 1 and 2were determined and the ORTEP
drawings showing the atom numbering scheme are projected in
Fig. 1. The selected bond lengths and angles are presented in
Table 2.
In compound 1 the ruthenium center adopts a distorted octahe-
dral geometry where the metal is bonded to two chelating ‘N,S-
SpymMe2’ ligands occupying the equatorial position of the
complex, with the chloride trans to the nitrosyl group in the apical
position completing the coordination sphere of the ruthenium
(Fig. 1A).
In this complex the NO group is almost linearly coordinated to
the Ru, with the Ru–N–O angle of 175.4 (3). This data, together
with the N–O distance of 1.152(4) Å, indicate a {Ru–NO+} type of
complex, as conﬁrmed by the IR spectrum (see below). The Ru–Cl
bond length of 2.3432(9) Å is typical of Cl trans NO, but shorter
than the Ru(II)–Cl distance, being consistent with the trans
strengthening effect of the NO, also known as ’inverse structural
trans effect’ [33]. The Ru–N(SpymMe2) bond distances are
2.081(3) and 2.093(3) Å for complex 1, which are comparable with
those found in pyridine and pyrimidine-2-thiolate complexes [23].
The Ru–S bonds for 1 [2.4301(9) and 2.4477(9) Å] are comparable
to the corresponding Ru–S distance found in complexes containing
the SpymMe2 or similar ligands [34].
In compound 2 the ruthenium center adopts a distorted octahe-
dral geometry where the metal ion is bonded to three chelating
ligands acting as bidentate (Fig. 1B). In this complex the Ru–N(Spy-
mMe2) bond distances are 2.1808(18) and 2.2300(17) Å, values
considerably longer than the observed for 1. Probably the trans ef-
fect exerced by the phosphorus atoms is responsible for such
observation in complex 2.
For both complexes the typical small bite angles of SpymMe2
are observed (N–Ru–S = 67.24 av.), which is a typical value for this
type of ligand [16]. The phosphorus atoms of 2 are disposed trans
to nitrogen atoms and the Ru–P distance is 2.264 Å av. The P–
Ru–P angles for the seven-membered ring of dppb in 2 is
94.46(2), which is comparable with the values previously ob-
served for other Ru–dppb complexes [16,35–37].
To sum up, although these structures are similar to others pre-
viously reported, in this case the structure of complex 1 presents
strong interaction between two monomers, which is maintaining
in solution, as shows its 1H NMR.
3.3. Characterization of the compounds
Complexes 1 and 2 are clearly neutral in nature, presenting the
conductivity values in CH2Cl2, close to zero lS cm1.
The 31P{1H} NMR spectrum of 2, in CDCl3 presents a singlet sig-
nal with chemical shifts at 47.5 ppm, indicating the chemical and
magnetic equivalence of the two phosphorus atoms of the dppb
ligand.
The coordination of the SpymMe2 thiolate ligand in complex 1
can be veriﬁed by three characteristic singlet signals in its 1H
NMR spectrum (in CDCl3): one in the aromatic region correspond-
ing to the hydrogen atom of the pyrimidinic ring and to twomethyl
groups attached to the same ring. However, complex 1 surpris-
ingly, showed two singlet signals at 7.20 and 6.70 ppm with 1:1
integration and also the expected aliphatic signals at 2.50 and
2.30 ppm with 6:6 integration. This observation can be explained
considering that the hydrogens of the different pyrimidinic rings
of 1 are submitted to different hydrogen interactions with sur-
rounding molecules as showed in Fig. 2.
It´s clearly observable that the H(9) of one molecule has the dis-
tance of 3.187 Å from the Cl(1) and of 3.316 Å from the N(2) atoms
of other neighboring molecules, when compared with the dis-
tances of 3.730 Å from H(3) and Cl(1) and of (4.294 Å) from N(4),
indicating a stronger intermolecular interaction with the ﬁrst set
of atoms.
By the 1H NMR data it is possible to assume that these interac-
tions have been kept in solution. In order to shed light in these
intermolecular interactions, to understand better the 1H NMR
Fig. 3. Packing diagram of 1 along the z axis. Color code: Ru, purple; Cl, green; N,
blue; O, red; C, grey; H, white; S, yellow. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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spectrum of the complex, calculations using the Energy Decompo-
sition Analysis, EDA, was employed [26]. The EDA allows us to ana-
lyze both, covalent and intermolecular interactions in different
levels of theory, such Hartree Fock method or Density Functional
Theory, DFT. For instance, at DFT level, the EDA decomposes the to-
tal Kohn–Sham energy interaction from a supramolecule calcula-
tion into electrostatic, exchange, repulsion, polarization and
dispersion components (Eq. 1) [26].
DEKS ¼ DEelstat þ DEexch þ DErep þ DEpol þ DEdisp ð1Þ
EDA analysis for 1 dimer was performed with M06/def2-SVP,
employing as monomers two interacting structures from unit cell.
The DEelstat ¼ 6:77 kcalmol1 component suggests the presence of
a small orbital overlapping between the two monomers, which is
also conﬁrmed by nonzero exchange-repulsion term
(DEexch þ DErep ¼ 31:14 kcalmol1). The DEpol ¼ 3:38 kcalmol1
value is quite small and indicates the monomer orbitals do not
change much in forming a dimer. As observed (Figs. 2 and 3), the
pyrimidinic rings of two monomers are quite close, suggesting
the presence of stacking interactions. The fact is conﬁrmed by
the contribution of the dispersion component,
DEdisp ¼ 35:57 kcalmol1 in EDA analysis, which can be consid-
ered the main drive force for the dimer formation, yielding a neg-
ative value for the total interaction energy,
DEKS ¼ 14:58kcalmol1, which conﬁrms the attractive nature of
the interaction between the two monomers.
The IR spectrum of the nitrosyl 1 shows an intense m (NO) band
at 1857 cm1, characteristic of a nitrosonium (NO+) ligand bonded
to ruthenium/phosphine species [15,17,36,38]. For both complexes
their IR spectra conﬁrm the presence of the SpymMe2 ligand coor-
dinated to the metal. The band attributable to the m(N–H), which
appears at 3200–3100 cm1 in free thiones is absent in the spectra
of the complexes, indicating that the SpymMe2 is coordinated in
the deprotonated form [39,40]. Bands from the coordinated ligand
SpymMe2 appear at approximately 1587 and 1529 cm1
(mC@C + mC@N), 1434 cm1 (mN@C + d CH) and at 1269, 1203 and
1183 cm1 (mC@S) for both complexes [39].
The cyclic voltammogram of the nitrosyl complex 1 was domi-
nated by redox process involving the NO+ ligand as well estab-
lished in the literature [38,41–43]. Thus, the cyclic voltammetric
experiments of complex 1, Fig. 4, showed quasi-reversible reduc-
tion processes at 700 mV (RuNO+? RuNOo) and at 1207 mV
(Ru–NOo? Ru–NO). After these reductions three anodic pro-
cesses appear in the cyclic voltammogram. The ﬁrst one, at
1207 mV(Ru–NO? Ru–NOo), the second, at 685 mV
(Ru–NOo? Ru–NO+), both of very low intensities and a third one,
of higher intensity, at 1110 mV, which could correspond to the oxi-
dation of the free NO generated in the electrochemical process
[43,44].
The electrochemical behavior of complex 2, in cyclic voltam-
metric experiments, was similar to that found for other com-
pounds, such as the [Ru(SpymMe2-N,S)(dppb)(N–N)]+, N–N = bipy
or Me-bipy [16]. A quasi-reversible one-electron RuII/RuIII redox
process was observed, Fig. 5, with E1/2 = 432 mV (Epa = 495 mV
and Epc = 369 mV; Ipa/Ipc = 1.01).
3.4. Cytotoxicity activity on cancer cell lines
The MDA-MB-231, Hela, U251 tumour cells and V79 cells were
exposed to each complex and to the free ligands for a period of 24
or 48 h, in order to allow them reach DNA or any other biological
target. Besides, for comparison, the cytotoxicity of cisplatin was
evaluated under the same experimental conditions. The IC50 val-
ues, calculated from the dose-survival curves generated by the
MTT or XTT assays obtained after drug treatment, are shown in
Table 3. Free ligandswere inactive against the three tumor cell lines.
One of the new complexes, the nitrosyl 1, is very active against
MDA-MB-231 breast human tumor, showing an IC50 value of
0.11 ± 0.02 lM. Several ruthenium(II) nitrosyl have showed signif-
icant cytotoxicity in human tumor cell lines, for example, the
cis-(Cl,Cl)-[RuCl2NO)(terpy)]Cl is very active against the A2780
and A2780cisR cell lines (IC50 close to 0.50 lM) [45] and the
(H2ind)[cis-RuCl4(NO)(Hind)] complex, where ind = indazole, and
Scheme 1. Routes for the synthesis of complexes 1 and 2.
Table 2
Selected bond distances (Å) and angles (o) for complexes 1 and 2.
1
N(1)–O(1) 1.152(4) Ru(1)–N(1)–O(1) 175.4(3)
Ru(1)–N(1) 1.733(3) N(1)–Ru(1)–Cl(1) 175.97(11)
Ru(1)–N(2) 2.093(3) N(1)–Ru(1)–N(2) 91.51(13)
Ru(1)–N(4) 2.081(3) N(1)–Ru(1)–N(4) 92.66(12)
Ru(1)–Cl(1) 2.3432(9) N(2)–Ru(1)–N(4) 175.75(11)
Ru(1)–S(1) 2.4477(9) S(1)–Ru(1)–S(2) 174.23(3)
Ru(1)–S(2) 2.4301(9) C(1)–S(1)–Ru(1) 79.76(13)
C(1)–S(1) 1.734(4) C(1)–N(2)–Ru(1) 103.1(2)
C(7)–S(2) 1.735(4) N(2)–Ru(1)–S(1) 67.28(8)
2
Ru(1)–N(1) 2.1808(18) N(1)–Ru(1)–N(4) 80.73(7)
Ru(1)–N(4) 2.2300(17) N(1)–Ru(1)–P(1) 162.58(5)
Ru(1)–P(1) 2.2602(5) N(4)–Ru(1)–P(1) 95.03(5)
Ru(1)–P(2) 2.2683(6) N(4)–Ru(1)–P(2) 167.46(5)
Ru(1)–S(2) 2.4120(5) P(1)–Ru(1)–P(2) 94.46(2)
Ru(1)–S(1) 2.4159(6) N(1)–Ru(1)–S(1) 67.09(5)
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other analogous, are active against A549, CH1 and SW480 human
tumor cell lines (IC50 in the range 0.83 to 35 lM) [46]. In these pa-
pers the authors suggested a possible role of NO in the observed
cytotoxicity, considering the multifunctional involvement of this
molecule in a number of physiological and pathological processes.
Also, the trans-[Ru(NO)(NH3)4(py)](BF4)3 is active against B16-F10
melanoma cells and, in the same way, the authors attributed cell
death to the release of NO promoted by reduction in the cell envi-
ronment [47]. In our case, for 1, also is possible the involvement of
the NO in the observed cytotoxicity, but it is important to note that
the chloro ligand can also be substituted, especially within cells
where the concentration of chloride ions is low [48]. In this sense
our complex act as prodrug, which will be active after some trans-
formation in the cell environment [6]. Recently our group pub-
lished the in vitro cytotoxicity and in vivo antitumour activity of
the cis-[RuCl2(NO)(BPA)] complex, BPA = 2-hydroxybenzyl)
(2-methylpyridyl)amine ion, showing its interaction with DNA,
indicating a clear pattern of DNA fragmentation, which is classi-
cally related with apoptosis [32].
The complex 1 showed a moderate activity against Hela and no
activity against U251 and showed a moderate activity in the Chi-
nese hamster ﬁbroblast cells line-V79 (normal cell). These results
indicate that this complex has a certain selectivity in its cytotoxic
action what could be important for future applications.
Finally, complex 1 showed in the same experimental conditions
higher activity than cisplatin, and also lower activity against the
normal cells V79.
On the other hand complex 2 was not active against the three
tumour cell lines used in this work. Unlike the nitrosyl complex,
this compound does not have any potential leaving group, consist-
ing of three stable chelating ligands. This factor probably is respon-
sible for the lack of activity observed for this complex.
4. Conclusion
In this investigation two new ruthenium complexes 1 and 2
were synthesized and characterized by elemental analysis, spec-
troscopic methods including crystal X-ray diffraction, conductime-
try and cyclic voltammetry.
The spectroscopic analysis was in agreement with the struc-
tures found by X-ray diffraction. An interesting structural observa-
tion was performed in the 1H NMR spectrum of complex 1 that
permitted to predict stronger intermolecular interactions in chlo-
roform solution. Energy decomposition analysis calculation indi-
cated strong intermolecular interaction between monomers of
complex 1, as suggested by the 1H NMR.
The in vitro cytotoxicity activity test utilizing the MDA-MB-231,
Hela, U251 human tumour cell lines indicated a high degree of
Fig. 4. Cyclic voltammogram (a) and differential pulse voltammogram (b) of complex 1 (ca. 1.0  103 M CH2Cl2 solution, 0.1 mol L1 TBAP, scan rate 100 mV s1, Ag/AgCl).
Fig. 5. Cyclic voltammogram of 2 (ca.1.0  103 M CH2Cl2 solution, 0.1 mol L1
TBAP, scan rate 100 mV s1, Ag/AgCl).
Table 3
IC50 values of complexes 1 and 2, free ligands and cisplatin measured in DMSO
solutions.
Compound IC50 (lM)
MDA-MB-231* Hela** U251** V79**
1 0.11 ± 0.02 18.7 ± 0.4 >200 22.3 ± 0.3
2 >200 >200 >200 75.0 ± 0.0
HSpymMe2 >200 >200 >200 103 ± 3
dppb >200 >200 >200 >200
cisplatin 88 ± 13 50 ± 3 26 ± 2 13 ± 4
IC50 = drug concentration at which 50% of the cells are viable relative to the control.
* MTT – 48 h.
** XTT – 24 h.
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cytotoxicity for complex 1, against MDA-MB-231 cell and reason-
able activity against Hela tumour cell, but not against the U251
cell. The complex 2 did not show cytotoxicity against all these
three tumour cells. These results indicate that the presence of leav-
ing groups in complex 1 can represent a highly advantageous for
the activity of this complex, when compared with 2. Further stud-
ies are necessary to demonstrate the mechanism of action of the
nitrosyl compound, 1.
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Appendix A. Supplementary data
Coordinates and other crystallographic data have been depos-
ited with the CCDC, deposition codes CCDC 937359 and 940581,
for the complexes 1 and 2, respectively. Copies of this information
may be obtained from The Director, CCDC, 12 Union Road, Cam-
bridge, CB2 1EZ, UK, Fax: +44 1233 336033, E-mail: deposit@ccdc.-
cam.ac.uk or www.ccdc.cam.ac.uk.
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